title: Risk factors for oxaliplatin-induced hypersensitivity reactions in Japanese patients with advanced colorectal cancer.
abstract: OBJECTIVE
  Previously, we suggested that oxaliplatin (L-OHP)-related grade 3/4 hypersensitivity reactions occurred immediately after the initiation, but grade 1/2 reactions did not. This study was conducted to clarify the risk factors for L-OHP-related hypersensitivity reactions.
  
  
  METHODS
  Clinical data from 108 Japanese patients with colorectal cancer were analyzed, who were treated with L-OHP-containing regimens, FOLFOX4 and/or mFOLFOX6. The risk factors examined included demographic data, preexisting allergies, laboratory test data, treatment regimen, treatment line of therapy, pretreatment with steroids, total number of cycles and cumulative amount of L-OHP.
  
  
  RESULTS
  The incidence of grade 1/2 and grade 3/4 hypersensitivity reactions were found at 13.0% (14/108) and 9.3% (10/108), respectively. Female (P = 0.037), preexisting allergies (P = 0.004) and lower level of lactate dehydrogenase (P = 0.003) were risk factors for grade 1/2 hypersensitivity reactions, and higher neutrophil count (P = 0.043) and lower monocyte count (P = 0.007) were for grade 3/4 reactions. Total number of cycles were larger in the patients with grade 3/4 reactions than those without reactions (P = 0.049).
  
  
  CONCLUSIONS
  Further extensive examination with a large number of patients is needed to establish a patient management strategy.
authors: Department of Pharmacy, Japan Labour Health and Welfare Organization, Kobe Rosai Hospital, Kobe 651-0053, Japan.
authors: Kyoko
authors: K
authors: Seki
authors: Kenzou
authors: K
authors: Senzaki
authors: Yasuo
authors: Y
authors: Tsuduki
authors: Takeshi
authors: T
authors: Ioroi
authors: Michiko
authors: M
authors: Fujii
authors: Hiroko
authors: H
authors: Yamauchi
authors: Yukinari
authors: Y
authors: Shiraishi
authors: Izumi
authors: I
authors: Nakata
authors: Kohshi
authors: K
authors: Nishiguchi
authors: Teruhisa
authors: T
authors: Matsubayashi
authors: Yoshihide
authors: Y
authors: Takakubo
authors: Noboru
authors: N
authors: Okamura
authors: Motohiro
authors: M
authors: Yamamori
authors: Takao
authors: T
authors: Tamura
authors: Toshiyuki
authors: T
authors: Sakaeda
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D015179:Colorectal Neoplasms / Q000150:complications / Q000188:drug therapy*; D004342:Drug Hypersensitivity / Q000175:diagnosis / Q000453:epidemiology*; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D006967:Hypersensitivity / Q000150:complications; D007564:Japan / Q000453:epidemiology; D007770:L-Lactate Dehydrogenase / Q000097:blood; D002955:Leucovorin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D007958:Leukocyte Count; D008297:Male; D008875:Middle Aged; D009000:Monocytes / Q000166:cytology; D009504:Neutrophils / Q000166:cytology; D009944:Organoplatinum Compounds / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D000077150:Oxaliplatin; D012307:Risk Factors; D012727:Sex Characteristics
chemical_list: D000970:Antineoplastic Agents; D009944:Organoplatinum Compounds; D000077150:Oxaliplatin; D007770:L-Lactate Dehydrogenase; D002955:Leucovorin; D005472:Fluorouracil